In the current study, we analyzed our well-followed patient cohort with intermediate- or high-risk prostate cancer who was treated with ≥7560 cGy to assess whether PSA nadir >0.5 ng/mL predicted for differences in all prostate cancer endpoints. The gene discussed is KLK3; the disease is prostate cancer.